El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Halozyme Therapeutics Inc
Abierto
SectorSalud
65.41 1.02
Resumen
Variación precio
24h
Mínimo
64.1
Máximo
65.56
Ingresos | -317M -142M |
|---|---|
Ventas | 98M 452M |
P/B Media del Sector | 26.617 61.417 |
Margen de beneficio | -31.342 |
Empleados | 423 |
EBITDA | -3.5M 281M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +38.44% upside |
Próximas Ganancias | 5 may 2026 |
|---|
Capitalización de Mercado | -1.3B 8B |
|---|---|
Apertura anterior | 64.39 |
Cierre anterior | 65.41 |
Noticias sobre sentimiento de mercado
By Acuity
36%
64%
89 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Bullish Evidence
Halozyme Therapeutics Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Halozyme Therapeutics Inc Esperado
Precio Objetivo
By TipRanks
38.44% repunte
Estimación a 12 meses
Media 89 USD 38.44%
Máximo 96 USD
Mínimo 75 USD
De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Halozyme Therapeutics Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
89 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por encima de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Live chat